BioSpace News Archive

Crinetics Pharmaceuticals, Inc. today announced the appointment of Caren Deardorf to the company’s board of directors.

Gracell Biotechnologies Inc. today reported fourth quarter and full year unaudited financial results for the period ended December 31, 2021, and provided corporate updates.

Titan Medical Inc. today announced that the company plans to issue its year end 2021 financial results prior to market opening on Thursday, March 24, 2022. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights.

Arch Therapeutics, Inc. today announced it has entered into a distribution agreement with Centurion Therapeutics Inc. to expand sales opportunities for AC5 ® Advanced Wound System.

Seer, Inc. announced the publication of a study demonstrating the performance of the technology platform underlying the Proteograph Product Suite™ for deep, unbiased, precise, scalable proteomics.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of Breast AI solutions, including ProFound AI® for Digital Breast Tomosynthesis (DBT) in the iCAD booth (#4000) at the 2022 Healthcare Information and Management Systems Society (HIMSS) Global Health Conference & Exhibition.

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), announced today that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of vonoprazan as a treatment for adults for the healing of all grades of erosive esophagitis (EE) and relief of heartburn, and maintenance of healing of all grades of EE and relief of heartburn.

Athenex, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Wednesday, March 16, 2022.

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), today reported two scientific presentations last week that included preclinical and patient sample data supporting the potential utility of its lead therapeutic candidate, CM-101, as a novel therapy for the treatment of systemic sclerosis (SSc).